New obesity pill shows promise in body fat reduction trial

NCT ID NCT07169942

Ongoing Disease control Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times

Summary

This study tests a new drug called aleniglipron (GSBR-1290) in 71 adults with obesity (BMI 30 or higher). Participants take the drug or a placebo daily for 40 weeks. The main goal is to see how much total body fat changes, measured by a special X-ray scan.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Phoenix, Arizona, 85020, United States
Research Site

Chicago, Illinois, 60602, United States
Research Site

Richfield, Minnesota, 55423, United States
Research Site

City of Saint Peters, Missouri, 63303, United States
Research Site

Rochester, New York, 14609, United States
Research Site

Wilmington, North Carolina, 28401, United States
Research Site

Norman, Oklahoma, 73069, United States
Research Site

Moncks Corner, South Carolina, 29461, United States
Research Site

North Charleston, South Carolina, 29405, United States
Research Site

Austin, Texas, 78704, United States
Research Site

San Antonio, Texas, 78240, United States

Conditions

Explore the condition pages connected to this study.

OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT